Pfizer Inc. (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Disruptive technologies, advanced analytics, and supercomputing platforms have played a vital role during Pfizer COVID-19 vaccine production, helping it identify the correct drug and used throughout the trials. Pfizer adopted AI as its core technology for conducting vaccine trials, vaccine processing, and streamlining its distribution. Pfizer’s prior investment in digital infrastructure, digitalization of R&D operations, and AI-enabled working systems further complemented its effort in producing and distributing the vaccine in less than a year.
The report provides information and insights into Pfizer’s tech activities, including -
- Insights of its digital transformation strategies and innovation hubs and accelerator programs
- Overview of technology initiatives covering partnerships, product launches and investments
- Insights on each technology initiative including technology theme, objective, and benefits
- Details of estimated ICT budgets and major ICT contracts
- In March 2021, Pfizer partnered with Iktos, a startup specialized in development of AI solution for clinical research. The partnership enabled Pfizer to deploy Iktos’ AI-based generative modelling technology, Makya for de novo design of small molecule drugs.
- Pfizer teamed up with Saama Technologies under Pfizer’s Breakthrough Change Accelerator, an incubation sandbox, to develop SDQ, an AI tool to boost the COVID-19 vaccine development process. The tool enabled Pfizer’s clinical team to maintain the data quality throughout the clinical trial and reduce the patients.
- In March 2021, Pfizer initiated the establishment of its technologically enabled sterile injectable pharmaceutical production facility dubbed as Modular Aseptic Processing (MAP) in Michigan. The company intends to equip this facility with virtual reality wearables like Oculus or Google Glasses for training, robotics, and isolator-based technology.
- In February 2021, Pfizer selected Seven Bridges, a bioinformatics company, to develop a data management and collaboration platform for the company’s single-cell ribonucleic aid (RNA) sequencing (scRNASeq) data. Further, Seven Bridges offers a cloud-based environment to Pfizer for performing bioinformatic analyses and enabling the research team to store, analyze and interpret data.
- In January 2021, Pfizer teamed up with WeRobotics, a provider of robotics solutions, to design a cargo drone by adding special features to M300, an industrial drone manufactured by DJI with AI capabilities and sensors. The drone will be used to distribute COVID-19 vaccines even to the remotest communities.
Reasons To Buy
- Gain insights into Pfizer’s tech operations.
- Gain insights into its tech strategies and innovation initiatives.
- Gain insights into its technology themes under focus.
- Gain insights into various product launches, partnerships, and investments strategies.